Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California. more
Time Frame | TSBX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.57% | -3.39% | 0.2% |
1-Month Return | 6.79% | -1.92% | 2.72% |
3-Month Return | -22.92% | -10.54% | 7.31% |
6-Month Return | -81.41% | -4.47% | 10.44% |
1-Year Return | -77.39% | 4.06% | 27.53% |
3-Year Return | -95.82% | 0.94% | 30.88% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | 101.29M | 73.30M | 19.31M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.36,"profit":true},{"date":"2023-12-31","value":19.06,"profit":true}] | ||
Cost of Revenue | 2.01M | 2.20M | 2.80M | [{"date":"2021-12-31","value":71.86,"profit":true},{"date":"2022-12-31","value":78.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Gross Profit | 99.28M | 71.10M | 16.51M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":71.61,"profit":true},{"date":"2023-12-31","value":16.63,"profit":true}] | ||
Gross Margin | 98.01% | 97.00% | 85.50% | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.96,"profit":true},{"date":"2023-12-31","value":87.23,"profit":true}] | ||
Operating Expenses | 68.30M | 104.93M | 78.34M | [{"date":"2021-12-31","value":65.09,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.66,"profit":true}] | ||
Operating Income | 32.99M | (31.63M) | (59.03M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.86,"profit":false},{"date":"2023-12-31","value":-178.92,"profit":false}] | ||
Total Non-Operating Income/Expense | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Pre-Tax Income | 33.70M | (30.69M) | (55.49M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-91.07,"profit":false},{"date":"2023-12-31","value":-164.64,"profit":false}] | ||
Income Taxes | 432.00K | 141.00K | (286.00K) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":32.64,"profit":true},{"date":"2023-12-31","value":-66.2,"profit":false}] | ||
Income After Taxes | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Income From Continuous Operations | 33.27M | (30.83M) | (52.42M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-92.68,"profit":false},{"date":"2023-12-31","value":-157.56,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | 33.27M | (30.83M) | (55.20M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-92.68,"profit":false},{"date":"2023-12-31","value":-165.92,"profit":false}] | ||
EPS (Diluted) | - | - | (9.29) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-929,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
TSBX | |
---|---|
Cash Ratio | 3.32 |
Current Ratio | 3.75 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TSBX | |
---|---|
ROA (LTM) | -66.10% |
ROE (LTM) | -134.46% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TSBX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.25 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.75 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TSBX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2.13 |
P/B | 0.25 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.80 |
Turnstone Biologics Corp. Common Stock (TSBX) share price today is $0.463
Yes, Indians can buy shares of Turnstone Biologics Corp. Common Stock (TSBX) on Vested. To buy Turnstone Biologics Corp. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TSBX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Turnstone Biologics Corp. Common Stock (TSBX) via the Vested app. You can start investing in Turnstone Biologics Corp. Common Stock (TSBX) with a minimum investment of $1.
You can invest in shares of Turnstone Biologics Corp. Common Stock (TSBX) via Vested in three simple steps:
The 52-week high price of Turnstone Biologics Corp. Common Stock (TSBX) is $5.75. The 52-week low price of Turnstone Biologics Corp. Common Stock (TSBX) is $0.4.
The price-to-earnings (P/E) ratio of Turnstone Biologics Corp. Common Stock (TSBX) is
The price-to-book (P/B) ratio of Turnstone Biologics Corp. Common Stock (TSBX) is 0.25
The dividend yield of Turnstone Biologics Corp. Common Stock (TSBX) is 0.00%
The market capitalization of Turnstone Biologics Corp. Common Stock (TSBX) is $13.39M
The stock symbol (or ticker) of Turnstone Biologics Corp. Common Stock is TSBX